Every year, a handful of biotech drugs redefine the boundaries of medical innovation and financial success. They aren’t just treatments — they are strategic assets that dictate the direction of research pipelines, pricing policies, and global healthcare investment. In 2025, the biotech sector stands on the edge of a massive revenue reconfiguration, led by a few blockbuster drugs that collectively generate hundreds of billions of dollars annually.
If you’re in pharma, life sciences, or healthcare marketing, understanding which drugs dominate global sales — and why — helps you make smarter business, investment, and go-to-market decisions. This is not about numbers alone. It’s about patterns, power shifts, and the next wave of opportunity.
The Biotech Landscape: Revenue at Scale
Biotechnology has evolved from being a niche science to becoming the core driver of pharmaceutical growth. The global biotech market was valued at approximately $1.55 trillion in 2023, with forecasts projecting it to reach $3.88 trillion by 2030, growing at a compound annual rate of 14%.
Within this space, biologics — large-molecule, protein-based therapies — now represent nearly half of global pharmaceutical revenue. Analysts project the global prescription drug market to reach $1.7 trillion by 2030, driven largely by oncology, immunology, and metabolic therapies.
These trends underscore a stark reality: a small number of drugs now control a disproportionate share of the industry’s financial outcomes. For executives and strategists, this concentration of power presents both opportunity and risk.
1. Keytruda (Pembrolizumab) – Merck & Co.
Merck’s Keytruda is not just the world’s top-selling drug — it’s a case study in how strategic lifecycle management can turn a molecule into a global phenomenon.
Keytruda generated approximately $29.5 billion in revenue in 2024, marking an 18% increase from the prior year. Forecasts from Evaluate Pharma suggest it will reach $31.5 billion in 2025 and $32.7 billion in 2026, before gradually declining post-2028 as biosimilar threats emerge.
Key factors behind its dominance include:
- Broad Indication Expansion: Keytruda has approvals across more than 35 cancer types, ranging from melanoma to non-small-cell lung cancer and renal carcinoma.
- Combination Strategy: The drug’s use alongside chemotherapy and targeted therapies has amplified its clinical and commercial reach.
- Formulation Innovation: Merck is preparing a subcutaneous version designed for patient convenience and to defend against biosimilars.
But Keytruda also exposes a key vulnerability. Nearly half of Merck’s total revenue depends on this one product. For you as a strategist or marketer, that’s a reminder that diversification is not optional. The market rewards focus — but it punishes overreliance.
2. Skyrizi and Rinvoq – AbbVie’s Dual Engine
When Humira — AbbVie’s long-standing blockbuster — lost exclusivity in early 2023, few expected the company to recover quickly. Yet, through Skyrizi (Risankizumab) and Rinvoq (Upadacitinib), AbbVie has executed one of the most successful post-patent transitions in biotech history.
- Skyrizi posted $11.7 billion in global sales in 2024, up from $7.8 billion the previous year.
- Rinvoq brought in nearly $6 billion in the same period.
- Combined, these two drugs are projected to surpass $31 billion in annual sales by 2027, offsetting most of Humira’s decline.
AbbVie achieved this through smart portfolio engineering:
- It built both drugs in overlapping therapeutic areas (immunology) to leverage existing sales and medical networks.
- It expanded indications beyond psoriasis to Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.
- It prioritized long-term value messaging over short-term price defense, positioning both as next-generation successors to Humira.
AbbVie’s success underscores the importance of strategic redundancy. When one blockbuster declines, the next must already be in motion.
3. Ozempic, Wegovy, and Mounjaro – The GLP-1 Revolution
No discussion about biotech dominance in 2025 is complete without mentioning the GLP-1 class of drugs. Originally designed for diabetes, these therapies have transformed into a cultural and economic phenomenon due to their weight-loss efficacy.
- Ozempic and Wegovy (Novo Nordisk) together generated over $35 billion in sales in 2024, more than doubling from 2023.
- Mounjaro and Zepbound (Eli Lilly) added another $10 billion, positioning Lilly as a strong rival.
- Combined, analysts forecast the GLP-1 market could exceed $100 billion in annual revenue by 2030, making it one of the largest therapeutic categories in pharmaceutical history.
Key strategic lessons for you:
- The demand surge shows how consumer perception and medical science can intersect. Weight loss moved from cosmetic concern to chronic disease management.
- Novo Nordisk and Lilly’s control over manufacturing capacity has created barriers to entry. Supply equals market power.
- The shift from diabetes to obesity and cardiometabolic indications demonstrates how therapeutic repositioning can multiply revenue potential.
If your business involves healthcare communication or marketing, understanding this paradigm is essential. GLP-1s are not just drugs — they’re a blueprint for modern pharma storytelling.
4. Beyond Blockbusters: The Next Generation of Growth
While Keytruda, Skyrizi, and Ozempic dominate today’s revenue charts, the next growth drivers are emerging from new modalities. The biotech industry is pivoting toward therapies that target the genetic and cellular roots of disease.
Upcoming categories to monitor include:
- RNA-Based Therapies: mRNA and RNA interference platforms are moving beyond vaccines into cardiology and rare diseases.
- Cell and Gene Therapy: Analysts expect these to generate more than $25 billion annually by 2030, as manufacturing costs fall.
- Bispecific Antibodies: These dual-target therapies are revolutionizing oncology by improving tumor specificity.
- CAR-T 2.0 Therapies: Expanding from hematologic malignancies into solid tumors, with improved durability and safety.
For executives, the message is simple: innovation pipelines will define competitive advantage far more than current sales rankings.
5. Revenue Concentration: Opportunity or Threat?
The biotech market’s growth is exciting but uneven. According to Evaluate Pharma and EY’s 2025 biotech outlook:
- The top 20 drugs account for nearly 30% of total pharmaceutical revenue.
- Oncology and immunology dominate, together representing more than 50% of the global market.
- The average development cost of a biologic exceeds $2 billion, but the returns — if successful — can surpass $20 billion annually.
This concentration has implications for everyone involved in the value chain:
- Investors must monitor patent cliffs closely; the loss of exclusivity can erase billions in market capitalization overnight.
- Marketers must prepare brand-extension campaigns years before biosimilar entry.
- Executives must balance risk by nurturing mid-size products to maturity rather than chasing only blockbuster ambitions.
Revenue leadership is fragile. Humira’s fall from $21 billion in 2022 to under $9 billion in 2024 is a warning for every market leader.
6. How to Read the Forecasts Correctly
Revenue forecasts can often appear like abstract numbers, but when decoded properly, they reveal actionable insights. Consider the following analytical framework:
- Identify Lifecycle Stage: Determine whether a drug is in early launch, growth, maturity, or decline. This shapes your pricing and messaging strategy.
- Map Competitive Entry: Evaluate when biosimilars or rival mechanisms will enter the same space. Early forecasting helps plan countermeasures.
- Watch for Indication Expansion: A single additional approval can extend a blockbuster’s commercial life by years.
- Track Real-World Evidence: Regulators and payers now prioritize post-market outcomes over trial promises. Real-world data drives payer retention.
By understanding these signals, you can convert forecasts into operational strategy — from budgeting and field-force deployment to data-driven marketing.
7. Where the Market Is Moving Next
Between 2025 and 2030, several forces will reshape biotech’s commercial structure. The most influential include:
- Patent Expirations
Dozens of top-selling biologics, including Keytruda and Stelara, will lose exclusivity before 2030. Biosimilar acceleration is inevitable. - Therapeutic Convergence
Diseases once treated in silos are merging in therapeutic strategy. Immunology, oncology, and metabolism now share overlapping pathways. - Manufacturing Scale
Capacity constraints have become strategic. The companies that master biologics manufacturing will control supply — and pricing. - Regulatory Simplification
Authorities like the FDA and EMA are modernizing frameworks for gene and cell therapies, which could compress approval timelines. - Pricing Transparency and Access Pressure
Policy shifts in the U.S. and Europe will continue to cap prices. Expect outcomes-based contracts and value-linked reimbursement models to grow.
These shifts demand that you think like a strategist, not a spectator. Revenue forecasting is no longer about estimation — it’s about adaptation.
8. Strategic Lessons for Biotech Leaders and Marketers
Success in biotech today is less about invention and more about integration — aligning science, supply, and storytelling. Based on current market dynamics, here are practical lessons you can act on immediately:
- Treat every blockbuster as a temporary asset. Begin replacement planning five years before exclusivity ends.
- Expand geographic reach early. Emerging markets such as India, Brazil, and the Middle East are set to drive double-digit growth in biologics demand.
- Invest in value demonstration. Clinical differentiation is not enough. Real-world outcomes, patient adherence, and digital support ecosystems now define market success.
- Leverage AI in commercialization. Predictive analytics can identify high-propensity prescribers, optimize field-force targeting, and personalize engagement.
- Create partnerships for manufacturing and data. No company can scale alone — alliances are increasingly the fastest route to market leadership.
For marketers, these aren’t abstract recommendations. They are operational playbooks drawn directly from the companies behind biotech’s biggest wins.
9. The Patient and Provider Perspective
Behind the billion-dollar revenue figures are real-world outcomes. Patients expect access, affordability, and efficacy. Providers want simplicity and proof of long-term benefit.
The best-performing biotech companies — from Merck to Novo Nordisk — understand this dual expectation. They don’t just sell therapies; they build ecosystems around them:
- Patient-support programs that enhance adherence
- Simplified dosing regimens to improve compliance
- Real-world data collection for continuous outcome measurement
If you lead marketing or communications in this sector, build narratives that align science with experience. In an era where trust defines adoption, perception is as critical as clinical data.
10. What the Future of Biotech Revenue Looks Like
By 2030, analysts expect more than 60% of the world’s top 20 drugs to be biologics. Oncology will remain the largest therapeutic area, followed by immunology, metabolic disease, and neurology.
But the nature of “blockbusters” will change. Instead of a few mega-drugs earning $30 billion each, the next generation will feature a wider base of high-value, niche therapies generating between $3–10 billion annually.
In essence, biotech is fragmenting into precision segments — smaller populations, higher margins, and faster product cycles. The challenge for you will be to manage this complexity while sustaining profitability.
Closing Insight
The story of biotech’s top-selling drugs is not about luck or timing — it’s about disciplined execution and long-term vision.
- Merck’s Keytruda demonstrates the value of indication expansion.
- AbbVie’s Skyrizi and Rinvoq showcase the art of transition planning.
- Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro highlight the power of market creation.
Together, these blockbusters reveal one consistent truth: biotech leadership requires balancing innovation with commercial foresight.
Ask yourself — is your organization preparing for the next Keytruda, or just reacting to it? The companies that anticipate change will define the next era of global healthcare economics.
References
- Top 50 Best-Selling Drugs to Watch in 2025 – xTalks
https://xtalks.com/top-50-best-selling-drugs-to-watch-in-2025-insights-from-2024-sales-data-4343/ - Evaluate 2030 Global Pharmaceutical Market Forecasts – Evaluate Ltd.
https://www.evaluate.com/press_release/evaluate-releases-2030-forecasts-for-global-pharmaceutical-market - Global Biotechnology Market Size & Industry Report, 2030 – Grand View Research
https://www.grandviewresearch.com/industry-analysis/biotechnology-market - Biotech Beyond Borders 2025 – EY
https://www.ey.com/en_us/life-sciences/biotech-outlook - Merck 2024 Financial Results – Merck & Co.
https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/ - AbbVie 2024 Full-Year Financial Report – PR Newswire
https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2024-financial-results-302364968.html - Skyrizi and Rinvoq Sales Projection to 2027 – Fierce Pharma
https://www.fiercepharma.com/pharma/abbvie-jacks-2027-sales-projection-skyrizi-and-rinvoq-31b - Top-Selling Drugs: Which Pharmaceuticals Are Driving Revenue – Patent PC
https://patentpc.com/blog/top-selling-drugs-which-pharmaceuticals-are-driving-revenue-market-data
